Short Interest in Heatwurx Inc. (NASDAQ:PCSA) Grows By 278.1%

Heatwurx Inc. (NASDAQ:PCSA) saw a significant increase in short interest in March. As of March 13th, there was short interest totaling 39,505 shares, an increase of 278.1% from the February 26th total of 10,448 shares. Approximately 1.5% of the company’s shares are short sold. Based on an average trading volume of 37,680 shares, the short-interest ratio is currently 1.0 days. Based on an average trading volume of 37,680 shares, the short-interest ratio is currently 1.0 days. Approximately 1.5% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Wall Street Zen downgraded Heatwurx from a “hold” rating to a “sell” rating in a research report on Saturday, February 14th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Heatwurx in a report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $25.00.

Heatwurx Stock Down 0.9%

PCSA stock opened at $2.33 on Wednesday. Heatwurx has a twelve month low of $1.76 and a twelve month high of $19.64. The firm has a market cap of $6.20 million, a price-to-earnings ratio of -0.07 and a beta of 1.05. The business’s fifty day simple moving average is $2.68 and its two-hundred day simple moving average is $4.96.

Heatwurx Company Profile

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.